BMY vs JNJ: Low Valuation or Steady Growth in Healthcare

Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ) are two healthcare giants facing investors' scrutiny. BMY focuses on high-impact areas like oncology, hematology, and cardiovascular health, with revenue reaching nearly $48.2 billion in fiscal 2025, a slight decrease from the previous year.

The company's valuation is low, trading at around 9.1x forward earnings, but it comes with risks such as patent expirations, government-mandated price controls under the Inflation Reduction Act, and ongoing patent disputes with Cytokinetics.

On the other hand, JNJ operates through innovative medicine and medtech, serving global markets with immunology and neuroscience treatments. Its revenue was about $94.2 billion in fiscal 2025, up nearly 6% year over year, with a net margin of around 28.5%. JNJ's financial position is more conservative, but it trades at a premium valuation.

The decision between BMY and JNJ depends on investors' priorities: low valuation and high dividend income for BMY or high profitability, steady growth, lower debt, and stronger cash flow for JNJ.